// App-Quantinova.ai

S205 : BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: A 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)

Researchers

Presenter

  • Martin Hutchings

Principal Investigators

  • Monika Dlugosz-Danecka

  • Joseph M. Connors

  • rpd Ills

  • Marco Picardi

  • Ewa Lech-Maranda

  • Tatyana Feldman

  • Piotr Smolewski

  • Kerry J. Savage

  • Nancy L. Bartlett

  • Jan Walewski

  • Radhakrishnan Ramchandren

  • Pier Luigi Zinzani

  • Javier Munoz

  • Won Seog Kim

  • Ranjana Advani

  • Stephen M. Ansell

  • Andrea Gallamini

  • Rachael Liu

  • Meredith Little

  • Keenan Fenton

  • Michelle Fanale

  • David J. Straus

Medical Centers

  • Research and Innovation, Antoine-Lacassagne Cancer Centre,Nice,France

  • Department of Medicine, Division of Oncology, Stanford University, Stanford, CA

  • University of Tennessee Graduate School of Medicine, Knoxville, TN

  • The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Hematology, Mayo Clinic, Rochester, Minnesota, United States

  • Department of Experimental Hematology,Medical University of Łódź,Łódź,Poland

  • Seràgnoli Institute of Hematology, Bologna University,Bologna,Italy

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • University of Debrecen, Debrecen, Hungary

  • Department of Oncology 5073 Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Hackensack University Medical Center, Oradell, NJ

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Seagen Inc.,Bothell, WA,United States

  • BC Cancer Centre for Lymphoid Cancer,Vancouver,Canadá

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Banner MD Anderson Cancer Center,Gilbert, AZ,États-unis

Locations

  • France

  • United States

  • United Kingdom

  • Poland

  • Italy

  • Republic of South Korea

  • Hungary

  • Denmark

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Peripheral Nervous System

Disease

  • Hodgkin's Lymphoma

  • Peripheral neuropathy

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01712490

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved